[A case of luminal B recurrent breast cancer with liver and lymph node metastases successfully treated with combination therapy of S-1 plus trastuzumab]

Gan To Kagaku Ryoho. 2010 Jul;37(7):1321-3.
[Article in Japanese]

Abstract

We experienced a case of Luminal B recurrent breast cancer with liver and lymph node metastases achieving significant improvement by S-1 plus trastuzumab combination therapy. This patient was a 47-year-old woman. Trastuzumab monotherapy was administered after recurrence, but her condition grew worse. Thus, we started combination therapy of trastuzumab plus S-1. S-1 was administered orally at 100 mg/day every day for 4 weeks followed by a 1-week rest period as one course, and trastuzumab was then injected at 2 mg/kg every week. All metastases disappeared after two courses of the treatment, and no new malignant lesions appeared. In conclusion, combination therapy of S-1 plus trastuzumab could be effective treatment for maintaining good QOL in Luminal B recurrent breast cancer with lymph node and liver metastases.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Drug Combinations
  • Female
  • Humans
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Lymphatic Metastasis / diagnostic imaging
  • Middle Aged
  • Oxonic Acid / administration & dosage
  • Oxonic Acid / therapeutic use*
  • Recurrence
  • Salvage Therapy
  • Tegafur / administration & dosage
  • Tegafur / therapeutic use*
  • Tomography, X-Ray Computed
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Trastuzumab